Search by Drug Name or NDC
NDC 00009-3701-05 Caverject 20.5 ug/mL Details
Caverject 20.5 ug/mL
Caverject is a INTRACAVERNOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Pharmacia & Upjohn Company LLC. The primary component is ALPROSTADIL.
MedlinePlus Drug Summary
Alprostadil injection and suppositories are used to treat certain types of erectile dysfunction (impotence; inability to get or keep an erection) in men. Alprostadil injection is also sometimes used in combination with other tests to diagnose erectile dysfunction. Alprostadil is in a class of medications called vasodilators. It works by relaxing the muscles and blood vessels in the penis to keep enough blood in the penis so that an erection can occur. Alprostadil does not cure erectile dysfunction or increase sexual desire. Alprostadil does not prevent pregnancy or the spread of sexually transmitted diseases such as human immunodeficiency virus (HIV).
Related Packages: 00009-3701-05Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Alprostadil Urogenital
Product Information
| NDC | 00009-3701 |
|---|---|
| Product ID | 0009-3701_b9809b81-2598-454c-9676-8d822786ce15 |
| Associated GPIs | 40303010002120 |
| GCN Sequence Number | 023796 |
| GCN Sequence Number Description | alprostadil VIAL 20 MCG INTRACAVER |
| HIC3 | F2A |
| HIC3 Description | DRUGS TO TREAT ERECTILE DYSFUNCTION (ED) |
| GCN | 02293 |
| HICL Sequence Number | 000177 |
| HICL Sequence Number Description | ALPROSTADIL |
| Brand/Generic | Brand |
| Proprietary Name | Caverject |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Alprostadil |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Route | INTRACAVERNOUS |
| Active Ingredient Strength | 20.5 |
| Active Ingredient Units | ug/mL |
| Substance Name | ALPROSTADIL |
| Labeler Name | Pharmacia & Upjohn Company LLC |
| Pharmaceutical Class | Genitourinary Arterial Vasodilation [PE], Prostaglandin Analog [EPC], Prostaglandin E1 Agonist [EPC], Prostaglandin Receptor Agonists [MoA], Prostaglandins [CS], Venous Vasodilation [PE] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA020379 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00009-3701-05 (00009370105)
| NDC Package Code | 0009-3701-05 |
|---|---|
| Billing NDC | 00009370105 |
| Package | 6 VIAL, SINGLE-DOSE in 1 PACKAGE (0009-3701-05) / 1 mL in 1 VIAL, SINGLE-DOSE (0009-3701-08) |
| Marketing Start Date | 1995-07-06 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |